• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Owens & Minor Inc. filed SEC Form 8-K: Regulation FD Disclosure

    7/23/24 6:52:35 AM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    8-K
    OWENS & MINOR INC/VA/ VA false 0000075252 0000075252 2024-07-22 2024-07-22

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 22, 2024

     

     

    OWENS & MINOR, INC.

    (Exact name of Registrant as specified in charter)

     

     

     

    Virginia   001-09810   54-1701843
    (State or other jurisdiction
    of incorporation)
      (Commission
    file number)
      (I.R.S. employer
    identification no.)

     

    9120 Lockwood Blvd.,
    Mechanicsville, Virginia
      23116
    (Address of principal executive offices)   (Zip code)

     

    Post Office Box 27626,
    Richmond, Virginia
      23261-7626
    (Mailing address of principal executive offices)   (Zip code)

    Registrant’s telephone number, including area code (804) 723-7000

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $2 par value per share   OMI   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 1.01.

    Entry Into a Material Definitive Agreement.

    Merger Agreement

    On July 22, 2024, Owens & Minor, Inc., a Virginia corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Rotech Healthcare Holdings Inc., a Delaware corporation (“Rotech”), Hitchcock Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the equity holders of Rotech (“Representative”). The Merger Agreement provides, among other things, that, upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Rotech (the “Merger”) with Rotech surviving the Merger as an indirect, wholly owned subsidiary of the Company, in exchange for an aggregate purchase price of $1.36 billion in cash, subject to customary adjustments for cash, debt, net working capital and transaction expenses, as set forth in the Merger Agreement. The cash consideration is expected to be funded through debt financing commitments.

    The closing of the Merger is subject to the satisfaction or waiver of certain customary closing conditions, including, among others, (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), (ii) the absence of any order, judgment or injunction that enjoins, makes illegal or otherwise prohibits the consummation of the Merger, (iii) completion of all filings and notices and the expiration or termination of all applicable notice or waiting periods under applicable healthcare regulatory notification laws, (iv) the accuracy of representations and warranties made by the Company, Merger Sub and Rotech, subject to certain specified materiality standards and certain exceptions, (v) performance and compliance by the parties of their respective covenants and obligations under the Merger Agreement in all material respects, and (vi) the absence of any Material Adverse Effect (as defined in the Merger Agreement) since the date of the Merger Agreement. Following the execution of the Merger Agreement, Rotech delivered to the Company an executed irrevocable written consent of stockholders of Rotech who collectively own a majority of the outstanding shares of common stock of Rotech (the “Rotech Majority Stockholders”), pursuant to which the Rotech Majority Stockholders adopted the Merger Agreement and approved and consented to the Merger and the consummation of the transactions contemplated thereby. No further approval by holders of shares of Rotech’s common stock is required to adopt the Merger Agreement or approve the Merger, or the other transactions contemplated by the Merger Agreement.

    Rotech made customary representations, warranties and covenants in the Merger Agreement, including, among others, and subject to certain exceptions, covenants to conduct its and its’ subsidiaries businesses and operations in the ordinary course of business during the period between the date of the Merger Agreement to the earlier of the closing date of the Merger and the termination of the Merger Agreement, not to engage in specified types of actions during this period.

    The Merger Agreement contains certain termination rights, including that either the Company or Rotech may terminate the Merger Agreement if, subject to certain limitations, the Merger has not closed by July 22, 2025 (the “Termination Date”).

    The Merger Agreement provides that the Company will be required to pay Rotech a termination fee of $70 million under certain specified circumstances if the expiration or termination of the applicable period under the HSR Act has not occurred or if any governmental authority issues a final and nonappealable injunction or order permanently enjoining or otherwise permanently preventing the consummation of the Merger and relating to an antitrust law, subject to the additional terms and conditions set forth in the Merger Agreement.

    The Company has obtained debt financing commitments to finance the transactions contemplated by the Merger Agreement and pay related fees and expenses pursuant to that certain commitment letter, dated as of July 22, 2024 (the “Commitment Letter”), between Citigroup Global Markets Inc. and the Company. Pursuant to the Commitment Letter, Citigroup Global Markets Inc., Citibank, N.A., Citicorp North America, Inc. and/or any of their affiliates (“Citi”) have agreed to provide committed acquisition debt financing in the form of (i) a term loan B facility under the Company’s existing Credit Agreement, dated as of March 29, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof) among the Company, the other


    borrowers party thereto, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A. (“JPM”), as collateral agent and administrative agent in an aggregate principal amount of $775 million and (ii) a senior unsecured bridge loan in an aggregate principal amount of $625 million (the “Bridge Facility”). The Bridge Facility availability is subject to reduction in equivalent amounts upon any incurrence by the Company of loans or notes prior to the consummation of the Merger and upon other specified events, subject to certain exceptions set forth in the Commitment Letter. The obligations of Citi to provide debt financing under the Commitment Letter are subject to a number of customary conditions.

    The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.01 to this Current Report on Form 8-K and incorporated herein by reference. The Merger Agreement has been included to provide investors with information regarding its terms. It is not intended to provide any other factual information about the Company, Rotech or any of their respective affiliates. In particular, the representations and warranties contained in the Merger Agreement were made only for the purposes of the Merger Agreement as of the specific dates therein, and were solely for the benefit of the parties to the Merger Agreement. The representations and warranties contained in the Merger Agreement may be subject to limitations agreed upon by the parties to the Merger Agreement and are qualified by information in confidential disclosure schedules provided in connection with the signing of the Merger Agreement. These confidential disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Moreover, certain representations and warranties in the Merger Agreement may be subject to a standard of materiality provided for in the Merger Agreement and have been used for the purpose of allocating risk among the parties, rather than establishing matters of fact. Investors are not third-party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company, Rotech or any of their subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the parties that is or will be contained in, or incorporated by reference into, the Company’s Annual Report on Form 10-K for the period ended December 31, 2023, Quarterly Report on Form 10-Q for the period ended March 31, 2024 and other documents that the Company has filed or will file with the Securities and Exchange Commission (the “SEC”).

     

    Item 7.01.

    Regulation FD Disclosure.

    On July 23, 2024, the Company and Rotech issued a joint press release announcing the transactions contemplated by the Merger Agreement. The Company has prepared an investor presentation, dated July 23, 2024, in connection with the announcement of the transactions contemplated by the Merger Agreement. On July 23, 2024 at 8:30 am Eastern time, the Company will hold a conference call to discuss the transactions contemplated by the Merger Agreement. The Company is furnishing the press release attached hereto as Exhibit 99.1 and the investor presentation attached hereto as Exhibit 99.2 pursuant to Item 7.01 of Form 8-K and each is incorporated by reference herein.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

    Forward Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the proposed Merger and the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. The Company cautions readers of this communication that such “forward looking statements,” wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.”


    Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the inability to complete the proposed Merger due to the failure to obtain approval of Rotech’s stockholders for the proposed Merger or the failure to satisfy other conditions to completion of the proposed Merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed Merger; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed Merger; the effect of the announcement of the proposed Merger on the Company’s relationships with its customers, suppliers and other third parties, as well as it operating results and business generally; the risk that the proposed Merger will not be consummated in a timely manner; exceeding the expected costs of the Merger; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve synergies or it may take longer than expected to achieve those synergies.

    Additional factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2023 and Quarterly Report on Form 10-Q for the period ended March 31, 2024, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

    The following exhibits are filed herewith:

     

    Exhibit    Description
     2.1*    Agreement and Plan of Merger, dated as of July 22, 2024, by and among the Company, Rotech, Merger Sub and Representative.
    99.1    Joint Press Release of the Company and Rotech, dated as of July 23, 2024 (furnished pursuant to Item 7.01).
    99.2    Investor Presentation, dated as of July 23, 2024 (furnished pursuant to Item 7.01).
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *

    Schedules and Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Agreement and Plan of Merger.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          OWENS & MINOR, INC.
    Date: July 23, 2024     By:  

    /s/ Heath H. Galloway

        Name:   Heath H. Galloway
        Title:   Executive Vice President, General Counsel & Corporate Secretary
    Get the next $OMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    11/3/2025$4.00Buy → Neutral
    UBS
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    More analyst ratings

    $OMI
    SEC Filings

    View All

    Amendment: Owens & Minor Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)

    1/5/26 4:05:19 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/31/25 4:15:43 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/18/25 4:18:47 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/10/25 9:43:55 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/7/25 8:21:15 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CEO P&HS Long Andrew G gifted 47,908 shares, decreasing direct ownership by 18% to 214,064 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    11/20/25 4:11:13 PM ET
    $OMI
    Medical Specialities
    Health Care

    EVP & CFO Leon Jonathan A covered exercise/tax liability with 4,265 shares, decreasing direct ownership by 2% to 218,522 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    9/24/25 4:07:31 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity

    The Transaction Includes the Owens & Minor Brand, and the Remaining Company Will Become Accendra Health Completes the Company's Transformation into a Pure Play Leader in the Home-Based Care Market Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc. "Today's announcement marks an inflection point in the strategic transformation of Owens & Minor into Accendra Health, a leading nationwide pure play home based care platform. The completion of the sale of the P&HS segment enables the Comp

    12/31/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.

    Accendra Health To Trade Under the "ACH" Symbol on the New York Stock Exchange Owens & Minor, Inc. (NYSE:OMI) ("the Company") today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31, 2025. The name change affects only the name of the parent corporation and is intended to better reflect the Company's strategic direction and future organizational focus as a leader in the home-based care market. The Company will continue to use and operate under the Apria and Byram Healthcare brands. "The renaming of our organization is another milestone in the strategic transformation of our company as a leading, pure play home-based care busin

    12/18/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025

    Owens & Minor, Inc. (NYSE:OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company's President and Chief Executive Officer, and Will Parrish, the Company's Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and host one-on-one investor meetings at the conference in Miami, Florida. Please visit the "Events & Presentations" section of the "Investor Relations" page on the Owens & Minor website available at https://investors.owens-minor.com at least

    12/2/25 7:00:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Owens & Minor downgraded by UBS with a new price target

    UBS downgraded Owens & Minor from Buy to Neutral and set a new price target of $4.00

    11/3/25 9:08:29 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor upgraded by Citigroup with a new price target

    Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

    7/19/24 7:41:01 AM ET
    $OMI
    Medical Specialities
    Health Care

    Leerink Partners initiated coverage on Owens & Minor with a new price target

    Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

    2/26/24 8:10:20 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Financials

    Live finance-specific insights

    View All

    Owens & Minor Reports Third Quarter 2025 Financial Results

    Signed Definitive Agreement for the Sale of Products & Healthcare Services Segment Transaction Positions the Company as a Pure-Play Home-Based Care Business Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. "Our recent announcement on the sale of our Products & Healthcare Services segment is another meaningful step in our strategy to pivot our focus to the more attractive home-based care space. We are keenly focused on reshaping ou

    10/30/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Date and Time Change of Third Quarter 2025 Financial Results and Conference Call

    Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the third quarter of 2025 on Thursday, October 30, 2025, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast c

    10/16/25 6:30:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for $375mm in Cash and a Retained Equity Stake

    Transforms Owens & Minor into a Pure Play Market Leader in the Home-Based Care Market 5% Retained Equity Stake Provides Ability to Realize Future Value Creation Under Platinum Equity Preserves Tax Attributes in Excess of $150 Million Owens & Minor, Inc. (NYSE:OMI) today announced that it has entered into a definitive agreement for the sale of the Company's Products & Healthcare Services (P&HS) segment to Platinum Equity. Over the last several years, Owens & Minor has been strategically moving towards expanding its leadership position in the very attractive home-based care space. This transaction will allow the Company to focus on a simpler business model and allow for a more appropria

    10/7/25 4:15:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

    Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

    6/22/22 6:50:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    11/12/24 10:32:12 AM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/13/24 5:12:07 PM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/12/24 5:29:41 PM ET
    $OMI
    Medical Specialities
    Health Care